医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

IGC Reports Financial Results for the Fiscal Year Ended March 31, 2020

2020年07月14日 AM05:45
このエントリーをはてなブックマークに追加


 

BETHESDA, Md.

India Globalization Capital, Inc. (NYSE American: IGC) announces its financial results for the Fiscal Year Ended March 31, 2020.

During Fiscal 2020, total revenue was approximately $4.1 million compared to approximately $5.1 million for Fiscal 2019. In both years, revenue was primarily derived from our India-based Infrastructure Business. In Fiscal 2020, the Company generated $411,000 revenue from its Life Sciences segment that was previously referred to as the Plant and Cannabinoid segment. Revenue in Fiscal 2020 was lower than Fiscal 2019 primarily due to economic slowdown, social distancing, travel and stay at home restrictions brought on by Covid-19 in the last quarter of our fiscal year.

The highlights for Fiscal 2020 are:

  1. We filed a provisional patent, IGC 510, Compositions and Methods using cannabidiol (“CBD”) for treating stammering and symptoms of Tourette syndrome with the USPTO.
  2. We received notification that on March 24, 2020, the USPTO issued a method and composition patent (#10,596,159 B2) for the Company’s cannabinoid formulation for the treatment of cachexia and eating disorders in humans and veterinary animals.
  3. The Company filed an Investigational New Drug Application with the FDA for a double-blind, placebo-controlled, 100-person trial, for its proprietary patent-pending formulation based on IGC-AD1 that uses ultra-low doses of cannabinoids with other natural compounds intended to assist in the management of the care of patients suffering from Alzheimer’s disease.
  4. We established a facility in San Juan, Puerto Rico to house and conduct clinical trials.
  5. We established a production and manufacturing facility in Washington State.
  6. The Company, in response to the Covid-19 pandemic, adapted the manufacturing facilities to produce and package hand sanitizers that are anticipated to go on sale in Fiscal 2021.
  7. We completed the development of several online and retail brands, building out our “house of CBD brands” that we anticipate will come to market in accordance with applicable law and regulation in the future.

General and administrative expenses for Fiscal 2020 was approximately $6 million as compared to approximately $3.5 million for Fiscal 2019. The increase is largely attributed to increased legal fees, and increased compensation expenses from an increased employee and contractor head count. We anticipate legal fees will abate over Fiscal 2021.

Research and Development (R&D) expense for Fiscal 2020 was approximately $1 million compared to approximately $1.3 million for the Fiscal 2019. The cost associated with this work is mostly research comprising of plant extracts, data to support the efficacy of extracts, and running FDA trials.

Net loss for Fiscal 2020 was approximately $7.3 million or $0.19 per share, compared to approximately $4.1 million or $0.13 per share for Fiscal 2019. The larger loss is largely attributed to increased legal and increased employee-related expenses.

On July 6, 2020, the United States District Court for the District of Maryland entered an order formally and finally approving a settlement that resolves all pending shareholder derivative suits filed against the Company between November 2018 and the present. Details of the settlement were previously disclosed on May 7, 2020 and in the Company’s public filings.

About IGC: IGC has two segments: Infrastructure and Life Sciences. The company is based in Maryland, U.S.A. Our website: www.igcinc.us.Twitter @IGCIR

Forward-looking Statements: This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on IGC’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, competitive conditions in the industries in which IGC operates, failure to commercialize one or more of the technologies of IGC, general economic conditions that are less favorable than expected, the Federal Food and Drug Administration’s (FDA) general position regarding hemp based products and our products in particular, the ongoing Covid-19 pandemic and its effect on the global and regional economies in which the Company participates, and other factors, many of which are discussed in our SEC filings. The Company incorporates by reference the Risk Factors identified in its Fiscal 2020 annual report filed with the SEC on Form 10-K on July 13, 2020. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will in fact occur.

India Globalization Capital, Inc.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

 

 

 

 

 

 

 

 

 

March 31,
2020

 

 

March 31,
2019

 

 

 

($)

 

 

($)

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

7,258

 

 

 

25,610

 

Marketable Securities

 

 

5,081

 

 

 

 

Accounts receivable, net

 

 

133

 

 

 

84

 

Inventories

 

 

4,245

 

 

 

248

 

Deposits and advances

 

 

1,040

 

 

 

781

 

Total current assets

 

 

17,757

 

 

 

26,723

 

 

 

 

 

 

 

 

 

 

Intangible assets, net

 

 

252

 

 

 

184

 

Property, plant and equipment, net

 

 

9,780

 

 

 

5,886

 

Non-Marketable Securities

 

 

11

 

 

 

794

 

Claims and advances

 

 

610

 

 

 

878

 

Operating lease asset

 

 

574

 

 

 

 

Total long-term assets

 

 

11,227

 

 

 

7,742

 

Total assets

 

 

28,984

 

 

 

34,465

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

 

762

 

 

 

319

 

Accrued liabilities and others

 

 

1,134

 

 

 

509

 

Short-term loan

 

 

50

 

 

 

50

 

Total current liabilities

 

 

1,946

 

 

 

878

 

 

 

 

 

 

 

 

 

 

Other liabilities

 

 

16

 

 

 

15

 

Operating lease liability

 

 

485

 

 

 

 

Total non-current liabilities

 

 

501

 

 

 

15

 

Total liabilities

 

 

2,447

 

 

 

893

 

 

 

 

 

 

 

 

 

 

Commitments and Contingencies – See Note 12

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 per value: authorized 1,000,000 shares, no share issued or outstanding as on March 31, 2020 and March 31, 2019

 

 

 

 

 

 

Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 39,320,116 and 39,501,407 shares issued and outstanding as on March 31, 2020 and March 31, 2019, respectively.

 

 

94,754

 

 

 

94,043

 

Accumulated other comprehensive loss

 

 

(2,850

)

 

 

(2,419

)

Accumulated deficit

 

 

(65,367

)

 

 

(58,052

)

Total stockholders’ equity

 

 

26,537

 

 

 

33,572

 

Total liabilities and stockholders’ equity

 

 

28,984

 

 

 

34,465

 

These financial statements should be read in connection with the accompanying notes on Form 10-K for the fiscal year ending March 31, 2020, filed with the SEC on July 10, 2020.

<td class="bwv

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • The China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells), an Investigational BCMA CAR-T Cell Therapy
  •  CG Creative Studios Wins Gold Stevie® Award in 2020 Asia-Pacific Stevie Awards
  • Largest Global Forensic DNA Meeting, International Symposium on Human Identification (ISHI), Going Virtual for 2020
  • Vyripharm International, Inc. and the National Yang-Ming University Signed a MOU to Develop VYR-206 as a Novel Diagnostic Approach for Neurological Disorders Outcomes Following Treatments
  • 患者安全運動財団、米国麻酔学会、ザ・リープフロッグ・グループ、医療の質に関する国際学会が世界患者安全の日キャンペーンの#UniteForSafeCareに向け力を合せる
  • India Globalization Capital, Inc.

    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (in thousands, except loss per share)

     

     

     

     

     

     

    Years Ended March 31,

     

     

     

    2020
    ($)

     

     

    2019
    ($)

     

    Revenues

     

     

    4,072

     

     

     

    5,116

     

    Cost of revenues

     

     

    (3,957

    )

     

     

    (4,984

    )

    Gross profit

     

     

    115

     

     

     

    132

     

    General and administrative expenses

     

     

    (5,968

    )

     

     

    (3,519

    )

    Research and development expenses

     

     

    (1,011

    )

     

     

    (1,256

    )

    Operating loss

     

     

    (6,864

    )

     

     

    (4,643

    )

    Impairment of investment

     

     

    (782

    )

     

     

     

    Other income – net

     

     

    331

     

     

     

    548

     

    Loss before income taxes

     

     

    (7,315

    )

     

     

    (4,095

    )

    Income taxes expense

     

     

     

     

     

    (2

    )

    Net loss attributable to common stockholders

     

     

    (7,315

    )

     

     

    (4,097

    )

    Foreign currency translation adjustments

     

     

    (431

    )

     

     

    (362

    )

    Comprehensive loss

     

     

    (7,746

    )

     

     

    (4,459

    )

     

     

     

     

     

     

     

     

     

    Loss per share attributable to common stockholders:

     

     

     

     

     

     

     

     

    Basic & diluted

     

    $

    (0.19

    )

     

    $